title: A novel combination therapy to reverse end-stage heart failure.
authors.affiliation: National Heart and Lung Institute at Imperial College of Science, Technology and Medicine, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom.
authors.forename: M H
authors.initials: MH
authors.lastname: Yacoub
authors.forename: P
authors.initials: P
authors.lastname: Tansley
authors.forename: E J
authors.initials: EJ
authors.lastname: Birks
authors.forename: N R
authors.initials: NR
authors.lastname: Banner
authors.forename: A
authors.initials: A
authors.lastname: Khaghani
authors.forename: C
authors.initials: C
authors.lastname: Bowles
authors.forename: W R
authors.initials: WR
authors.lastname: Banner
authors.forename: A
authors.initials: A
authors.lastname: Khaghan
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003971:Diastole; D004452:Echocardiography; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006353:Heart-Assist Devices; D006801:Humans; D013599:Systole; D013927:Thrombosis / Q000517:prevention & control; D018487:Ventricular Dysfunction, Left / Q000628:therapy*; D016277:Ventricular Function, Left / Q000502:physiology*
chemical_list: D000319:Adrenergic beta-Antagonists